Cargando…
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)
BACKGROUND: The prostate tumor microenvironment (TME) is immunosuppressive, with few effector T cells and enrichment of inhibitory immune populations, leading to limited responses to treatments such as immune checkpoint therapies (ICTs). The immune composition of the prostate TME differs across soft...
Autores principales: | Siddiqui, Bilal A, Chapin, Brian F, Jindal, Sonali, Duan, Fei, Basu, Sreyashi, Yadav, Shalini S, Gu, Ai-Di, Espejo, Alexsandra B, Kinder, Michelle, Pettaway, Curtis A, Ward, John F, Tidwell, Rebecca S S, Troncoso, Patricia, Corn, Paul G, Logothetis, Christopher J, Knoblauch, Roland, Hutnick, Natalie, Gottardis, Marco, Drake, Charles G, Sharma, Padmanee, Subudhi, Sumit K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040066/ https://www.ncbi.nlm.nih.gov/pubmed/36948506 http://dx.doi.org/10.1136/jitc-2022-006262 |
Ejemplares similares
-
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
por: Subudhi, Sumit K, et al.
Publicado: (2021) -
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies
por: Perez de Acha, Olivia, et al.
Publicado: (2023) -
An (89)Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor
por: Mason, Christian A., et al.
Publicado: (2020) -
IMMU-21. INVESTIGATION OF WHITE BLOOD CELL CHARACTERISTICS IN CSF SAMPLES AT PEDIATRIC BRAIN TUMOR DIAGNOSIS
por: Greer, Hunter, et al.
Publicado: (2020) -
IMMU-02. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL NEUROTOXICITY CORRELATES WITH PRETREATMENT AND ACUTE CSF NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS
por: Gust, Juliane, et al.
Publicado: (2020)